CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.62BCNY540.64M · vs all stocks (USD)
Revenue (TTM)
278.46MCNY41.57M · vs all stocks (USD)
Profit Margin
-9.61%vs Biotechnology peers
Beta
0.5420xvs all stocks
52-Week Change
-16.95%vs all stocks
Market Capitalization
3.62BCNY540.64M · vs all stocks (USD)
Enterprise Value
3.42BCNY510.69M · vs all stocks (USD)
Price to Sales (TTM)
12.30xvs Biotechnology peers
Price to Book (MRQ)
2.45xvs Biotechnology peers
Enterprise to Revenue
12.29xvs Biotechnology peers
Enterprise to EBITDA
88.41xvs Biotechnology peers
Gross Margin
49.89%vs Biotechnology peers
Profit Margin
-9.61%vs Biotechnology peers
Operating Margin
-41.11%vs Biotechnology peers
Return on Assets (TTM)
-1.36%vs Biotechnology peers
Return on Equity (TTM)
-2.16%vs Biotechnology peers
Revenue (TTM)
278.46MCNY41.57M · vs all stocks (USD)
Revenue per Share (TTM)
0.7200CNYUpdated Sep 22, 2026Quarterly Revenue Growth
14.70%vs Biotechnology peers
Gross Profit (TTM)
156.41MCNY23.35M · vs all stocks (USD)
EBITDA (TTM)
60.30MCNY9.00M · vs all stocks (USD)
Net Income (TTM)
-26.77MCNY-4.00M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-37.36%vs Biotechnology peers
Operating Cash Flow (TTM)
7.80MCNY1.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-47.91MCNY-7.15M · vs all stocks (USD)
5-Year Average Dividend Yield
0.90%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
9.85MCNYFY2025 · Dec 31, 2025Revenue
288.27MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
124.47MCNYFY2025 · Dec 31, 2025Gross Profit
163.79MCNYFY2025 · Dec 31, 2025Operating Income
-14.23MCNY-2.12M · vs all stocks (USD)
Pre-tax Income
-26.31MCNYFY2025 · Dec 31, 2025Income Tax Expense
-1.34MCNYFY2025 · Dec 31, 2025Net Income
-24.97MCNYFY2025 · Dec 31, 2025EBIT
-25.78MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
60.30MCNYFY2025 · Dec 31, 2025Research & Development
44.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
80.03MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
625.11KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
532.06KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
409.90MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
409.90MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-24.97MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.48MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-59.34MCNYFY2025 · Dec 31, 2025Free Cash Flow
-104.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
91.58MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-24.97MCNYFY2025 · Dec 31, 2025Other Non-cash Items
580.99KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-34.22MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-727.70KCNYFY2025 · Dec 31, 2025Capital Expenditures
-44.72MCNYFY2025 · Dec 31, 2025Purchase of Investments
-598.00MCNYFY2025 · Dec 31, 2025Sale of Investments
593.55MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-49.16MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.12MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-265.69KCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.51MCNYFY2025 · Dec 31, 2025Shares Outstanding
410.64MSharesUpdated Sep 22, 2026Float Shares
221.22MSharesUpdated Sep 22, 2026% Held by Insiders
55.62%vs all stocks
% Held by Institutions
0.53%vs all stocks
Total Cash (MRQ)
65.59MCNY9.79M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1600CNYUpdated Sep 22, 2026Total Debt (MRQ)
53.45MCNY7.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0383xvs Biotechnology peers
Current Ratio (MRQ)
3.54xvs Biotechnology peers
Book Value per Share (MRQ)
3.41CNYUpdated Sep 22, 2026Total Assets
1.54BCNY230.23M · vs all stocks (USD)
Total Current Assets
535.90MCNYFY2025 · Dec 31, 2025Total Liabilities
143.41MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.01BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
10.08MCNYFY2025 · Dec 31, 2025Total Current Liabilities
133.33MCNYFY2025 · Dec 31, 2025Cash
91.57MCNYFY2025 · Dec 31, 2025Cash Equivalents
30.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
122.00MCNYFY2025 · Dec 31, 2025Other Short-term Investments
32.82MCNYFY2025 · Dec 31, 2025Accounts Receivable
282.11MCNYFY2025 · Dec 31, 2025Inventory
94.47MCNYFY2025 · Dec 31, 2025Accounts Payable
16.43MCNYFY2025 · Dec 31, 2025Short-term Debt
13.26MCNYFY2025 · Dec 31, 2025Other Current Liabilities
8.63MCNYFY2025 · Dec 31, 2025Long-term Debt
915.79KCNYFY2025 · Dec 31, 2025Common Stock (Book)
410.64MCNYFY2025 · Dec 31, 2025Retained Earnings
384.23MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.40BCNY208.82M · vs all stocks (USD)
Treasury Stock
20.00MCNYFY2025 · Dec 31, 202552-Week Low
7.29CNYUpdated Sep 22, 202652-Week High
12.36CNYUpdated Sep 22, 202652-Week Change
-16.95%vs all stocks
Beta
0.5420xvs all stocks
50-Day MA
8.36CNYUpdated Sep 22, 2026200-Day MA
8.83CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.97MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.37MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.0700CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.50Profit Margin: -0.10
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule